Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Collateral Therapeutics (NasdaqNM:CLTX)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Financials | Reports
Recent Events
Aug 14Earnings Announcement
July 27Price hit new 52-week low ($5.67)
Location
11622 El Camino Real
San Diego, CA 92130
Phone: (858) 794-3400
Fax: (858) 794-3440
Email: info@collateralthx.com
Employees (last reported count): 66
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Investor Relations
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 64%
·Institutional: 35% (97% of float)
(62 institutions)
·Net Inst. Selling: 185.0K shares (+4.12%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Collateral Therapeutics, Inc. is focused on the discovery and development of non-surgical gene therapy products for the treatment of cardiovascular diseases, including coronary artery disease, peripheral vascular disease, congestive heart failure and heart attacks. The Company's initial gene therapy products are designed to promote and enhance angiogenesis, a natural biological process that results in the growth of additional blood vessels to increase levels of blood flow to oxygen-deprived tissues. In collaboration with its partner, Schering AG, in May 1998, the Company began early stage testing in humans, known as a Phase I/II trial, for Generx, the first of its gene therapy product candidates. In January 2001, based on results from the Phase I/II trial, Collateral reported plans to proceed with Phase IIb/III clinical trials of Generx. Its non-surgical gene therapy product candidates use technology that includes methods of gene therapy, therapeutic genes and gene delivery vectors.
More from Market Guide: Expanded Business Description

Financial Summary
Collateral Therapeutics is focused on the discovery, development and commercialization of non-surgical gene therapy products for the treatment of cardiovascular diseases. For the six months ended 6/30/01, revenues fell 14% to $1.2 million. Net loss increased 26% to $8.2 million. Revenues reflect decreased R and D support to the company under the Schering AG agreement. Higher loss also reflects increases in personnel costs, lab supplies and rent expense.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Jack Reich, Ph.D., 52
CEO, Chairman
$686K--  
Christopher Reinhard, 47
Pres, COO, Chief Financial Officer, Director
487K--  
Tyler Dylan, Ph.D., 39
VP, Gen. Counsel, Sec.
284K--  
Jeffrey Friedman, M.D., 54
VP- Devel.
295K$7.1K
Patricia Novak, Ph.D., 49
VP, Product Management
--  --  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:CLTXAs of 31-Aug-2001
Price and Volume
52-Week Low
on 27-July-2001
$5.67 
Recent Price$7.05 
52-Week High
on 17-Nov-2000
$32.25 
Beta1.71 
Daily Volume (3-month avg)25.2K
Daily Volume (10-day avg)19.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y]
52-Week Change-74.8%
52-Week Change
relative to S&P500
-66.2%
Share-Related Items
Market Capitalization$93.5M
Shares Outstanding13.3M
Float4.80M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$1.43 
Earnings (ttm)-$1.24 
Earnings (mrq)-$0.34 
Sales (ttm)$0.14 
Cash (mrq)$1.30 
Valuation Ratios
Price/Book (mrq)4.92 
Price/EarningsN/A 
Price/Sales (ttm)51.44 
Income Statements
Sales (ttm)$1.80M
EBITDA (ttm)-$16.4M
Income available to common (ttm)-$16.3M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-51.90%
Return on Equity (ttm)-59.33%
Financial Strength
Current Ratio (mrq)4.30 
Debt/Equity (mrq)0.11 
Total Cash (mrq)$17.2M
Short Interest
As of 8-Aug-2001
Shares Short120.0K
Percent of Float2.5%
Shares Short
(Prior Month)
148.0K
Short Ratio8.00 
Daily Volume15.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Some event data provided by CCBN. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.